Interest is growing in discussions by the Ministry of Health, Labor and Welfare’s (MHLW) new expert panel on comprehensive pharmaceutical measures. At its meeting on September 22, major trade groups made their cases to push for a re-think of the…
HOME > LATEST
LATEST
-
BUSINESS Novo Seeks Japan Approval of Hemophilia Drug Concizumab
August 31, 2022
-
ORGANIZATION Allocate All Savings from Off-Year Drug Re-Pricing to Medical Fees: Hodanren
August 31, 2022
-
BUSINESS Viatris Launches Japan PIII to Add GAD Indication for Effexor SR
August 31, 2022
-
BUSINESS Taiho’s GIST Drug Jeselhy Now Available in Japan
August 31, 2022
-
BUSINESS Daiichi Sankyo Files Vanflyta for Frontline AML in Japan
August 31, 2022
-
REGULATORY Japan Approves AstraZeneca’s COVID-19 Cocktail Therapy Evusheld
August 30, 2022
-
REGULATORY Pfizer’s COVID Booster Approved for Children Aged 5-11 in Japan
August 30, 2022
-
REGULATORY LDP Group Eyes Proposal on Generic Distribution, Pricing; Expert Wants Penalty on Healthcare Providers Getting Undue Discounts
August 30, 2022
-
BUSINESS Stelues Shipments to Get Back to Normal in September: Pfizer Japan
August 30, 2022
-
REGULATORY AZ’s Asthma Drug Tezepelumab Clears MHLW Panel Review; BMS’ Psoriasis Med, MSD/Sanofi Jabs Too
August 30, 2022
-
REGULATORY AstraZeneca’s COVID Cocktail in Line for Approval, Comirnaty Booster for Ages 5-11
August 30, 2022
-
REGULATORY Japan Eyes FY2023 Launch of Pandemic Response Agency
August 29, 2022
-
COMMENTARY Tussle in Japan Diabetes Market Heating Up; BI and Sumitomo Nip and Tuck for No. 1 Slot
August 29, 2022
-
BUSINESS Kymriah Now Approved for Follicular Lymphoma in Japan: Novartis
August 29, 2022
-
REGULATORY MHLW’s Health Service Bureau to Seek Funding for “Income Security System” for Antimicrobials for FY2023
August 29, 2022
-
REGULATORY MHLW’s Health Policy Bureau to Seek Budget for Research into Integrating Drug Supply Info, Clarification of Generic Ratio
August 29, 2022
-
REGULATORY MHLW Begins Discussions on Potential Use of Non-Doctor/Nurse Healthcare Professionals as Vaccinators
August 29, 2022
-
BUSINESS Minomycin Supply Resumption to Be Delayed: Pfizer
August 26, 2022
-
BUSINESS Pfizer Files Ritlecitinib for Alopecia Areata Treatment in Japan
August 26, 2022
-
REGULATORY MHLW’s Pharma Bureau to Request Budget to Promote RWD Use in Regulatory Filing for FY2023
August 26, 2022
ページ
Healthcare in the US is a highly political topic, with one end of the political spectrum arguing for broader government-sponsored access and the other advocating for more of a free-market approach. While the US market has typically been the primary…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…